Turning Point Therapeutics Names Andrew Partridge As Executive Vice President and Chief Commercial Officer
Turning Point Therapeutics (NASDAQ: TPTX) announced the appointment of Andrew Partridge as executive vice president and chief commercial officer, effective immediately. Partridge brings over 20 years of pharmaceutical sales and marketing experience, having led more than 20 commercial launches in oncology and rare diseases. His prior roles include positions at Centrexion Therapeutics and Vertex Pharmaceuticals, where he successfully launched cystic fibrosis therapies. Turning Point’s lead candidate, repotrectinib, targets key genetic drivers in cancer, with ongoing registrational studies indicating promising antitumor activity.
- Appointment of Andrew Partridge as chief commercial officer to enhance market strategies.
- Partridge's extensive background in oncology and successful commercial launches may drive growth.
- Lead drug candidate repotrectinib shows antitumor activity in ongoing studies.
- None.
SAN DIEGO, July 13, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Andrew Partridge as executive vice president and chief commercial officer, effective today. Mr. Partridge has more than 20 years of global pharmaceutical sales and marketing experience leading more than 20 commercial launches across multiple indications, including oncology, hematology and rare diseases.
“As we progress our global registrational study of repotrectinib and with three other earlier stage drug candidates in our pipeline, I am pleased to have a commercial veteran of Andy’s caliber to lead our market planning and commercialization efforts,” said Dr. Athena Countouriotis, president and chief executive officer. “His depth of experience preparing for and successfully executing multiple commercial launches will serve us well and makes him an ideal fit for our team.”
Mr. Partridge joins the company from Centrexion Therapeutics, a privately held biotech, where he served as both chief operating officer and chief commercial officer. He was previously with Vertex Pharmaceuticals for 5 years, most recently as senior vice president and head of North American commercial operations where he built the team to successfully launch multiple cystic fibrosis therapies and new indications. Mr. Partridge had overall responsibility at Vertex across the U.S. and Canada for marketing, sales, market access and patient services and led the cross-functional North American leadership team that included medical affairs, finance, legal and human resources. In the preceding 20 years, he served in sales and marketing roles of increasing responsibility with Schering-Plough, Roche and Amgen. At Amgen, he held senior marketing and sales roles for oncology and hematology therapeutics, including strategic planning and operations of the
“Precision medicine offers new hope to patients with genetically driven cancers, and Turning Point has an exciting pipeline of drug candidates that could potentially address multiple difficult to treat indications,” said Mr. Partridge. “I look forward to working closely with Athena and the team on commercial planning and launch readiness, with the goal of getting critical therapies to patients as quickly as possible.”
About Turning Point Therapeutics Inc.
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company’s pipeline of drug candidates also includes TPX-0022, targeting MET, CSF1R and SRC, which is being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET and SRC, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; and TPX-0131, a next-generation ALK inhibitor in IND-enabling studies. Turning Point’s next-generation kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment. For more information, visit www.tptherapeutics.com.
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the efficacy, safety, and therapeutic potential of Turning Point Therapeutics’ drug candidates the progress of Turning Point Therapeutics’ development programs, and plans regarding future development and commercial activities. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “plans”, “will”, “believes,” “anticipates,” “expects,” “intends,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Turning Point Therapeutics’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Turning Point Therapeutics’ business in general, risks and uncertainties related to the impact of the COVID-19 pandemic to Turning Point’s business and the other risks described in Turning Point Therapeutics’ filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Contact:
Jim Mazzola
jim.mazzola@tptherapeutics.com
858-342-8272
FAQ
Who is the new chief commercial officer of Turning Point Therapeutics?
What is the stock symbol for Turning Point Therapeutics?
What is the lead drug candidate of Turning Point Therapeutics?
What experience does Andrew Partridge bring to Turning Point Therapeutics?
What are the ongoing studies for repotrectinib?
